Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Regular budget reviews create consistency, reveal trends, and enable proactive adjustments to keep your finances on a steady, healthy course.
26,498 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Cardano is sparking renewed trader interest as ADA price predictions point to a potential rally. Analysts cite chart ...
WeWork and Upwork CEOs acknowledge a continuing Gen Z hiring crunch amid AI disruption, stressing mentorship and lead...
A lone IBIT block trade worth about $1.26 billion crossed the tape at $43.16 per share, yet the ETF barely budged. Bi...
Bitmine filed for a public offering of 3 million shares of a 9.50% perpetual preferred stock to accelerate ETH holdin...
A fresh Iran ceasefire reshapes inflation expectations and energy markets, giving the Fed more room to maneuver. Inve...
A nobel laureate economist warns that anxiety about AI displacing workers risks shaping real outcomes, not just headl...
South Korea’s memory-chip giant SK Hynix plans a Nasdaq debut with a roughly $29 billion offer, aiming to test if AI-...
Wall Street traders weigh a contrarian opportunity as Pfizer and Gilead trade below fair value amid rising bearish se...
The Supreme Court will hear a Boulder County climate-liability case against major oil producers, a move that could re...
Bitcoin gauges snap shut as the Binance BTC derivatives index slides to 0.35, prompting bets on whether a rebound or ...
The stablecoin bill enters final stage as negotiators confront whether non-bank issuers can offer yield on reserves. ...